We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
Read MoreHide Full Article
Sanofi (SNY - Free Report) and partner Teva Pharmaceuticals (TEVA - Free Report) announced positive data from the phase IIb RELIEVE UCCD study on their investigational anti-TL1A therapy, duvakitug (formerly TEV’574), for the treatment of Ulcerative Colitis (UC) and Crohn's disease (CD), the two main types of inflammatory bowel disease (IBD). The study met its primary endpoints for both diseases.
Treatment With SNY-TEVA Drug Exhibits Best-in-Class Potential
In the UC group, 36.2% of patients who received a low dose of the drug and 47.8% of patients who received a high dose achieved clinical remission compared to 20.45% for placebo.
For the CD group, 26.1% of patients who received a low dose and 47.8% of patients who took a high dose achieved endoscopic response compared to 13% in the placebo group.
Based on the above results and subject to regulatory discussions, Sanofi and Teva intend to start a late-stage study on the drug across both UC and CD indications.
The companies also plan to report detailed results from the RELIEVE UCCD study at a medical meeting next year.
Stock Performances of SNY & TEVA
Investors were impressed with the study results, which sent shares of both Sanofi and Teva soaring on Tuesday. Some Wall Street analysts even pointed out that the results for the Sanofi-Teva drug were even better than those reported by rivals Merck and Roche, which are also developing their respective anti-TL1A therapies.
Sanofi stock rose nearly 7%. Year to date, the stock fell 1.6% against the industry’s 5.3% growth.
Image Source: Zacks Investment Research
Shares of Teva jumped 26% post the announcement, even hitting a six-year high of $21.05. Year to date, the stock has doubled in market value compared with the industry’s 11.2% growth.
Image Source: Zacks Investment Research
Terms of Partnership Between SNY & TEVA
Last year, Sanofi in-licensed joint development and commercialization rights from Teva for duvakitug. Per the agreement terms, Teva will lead the commercialization of duvakitug in Europe, Israel and specified other countries, while Sanofi will be responsible for commercializing the drug in North America, Japan, other parts of Asia and the rest of the world.
Per the terms, Sanofi and Teva will equally share the development costs of duvakitug globally, as well as net profits and losses in major markets. In other markets, SNY will be liable to make tiered royalty payments to Teva on the drug’s net sales. Sanofi will lead the upcoming phase III development program for duvakitug.
In return for these rights, SNY paid TEVA an upfront payment of $500 million. Teva is also eligible to receive up to $1 billion in milestone payments.
Competition in the IBD Space
Both UC and CD indications are primary forms of IBD, marked by chronic inflammation in the gastrointestinal tract. In recent years, there has been a surge in the prevalence of these disorders due to genetic factors, environmental factors and lifestyle changes. Immune system irregularities, higher diagnosis rates, increased focus on early diagnosis and favorable reimbursement policies in developed countries drive the demand for IBD treatments.
The targeted IBD market is highly competitive. Some key players in this space are Johnson & Johnson (JNJ - Free Report) and AbbVie (ABBV - Free Report) , which have the strongest portfolios of immunology drugs and pipeline candidates.
J&J boasts a strong immunology portfolio with blockbusters like Stelara and Tremfya. A much older drug, Stelara, is already approved to treat several IBD indications, including CD and UC, across the United States and the European Union. J&J added more than $8 billion from Stelara sales in the first nine months of 2024.
Another successful drug in J&J’s portfolio is its newer immunology drug, Tremfya, which recorded sales of $2.7 billion in the first nine months of 2024. Tremfya was approved by the FDA for UC indication in September, with a similar regulatory filing under review in the European Union. It is also under review by the FDA and EMA for CD indication. J&J expects Tremfya to be a $5 billion product with potential approvals in both CD and UC indications.
ABBV’s key immunology products, Skyrizi and Rinvoq, are performing extremely well, bolstered by approval across multiple IBD indications, which should support top-line growth in the next few years. AbbVie has already raked in nearly $10 billion from the combined product sales of both these drugs in the first nine months of 2024.
ABBV has also been engaged in an acquisition spree since the beginning of this year to strengthen its leadership in the immunology space. In 2024, it acquired smaller biotechs, Landos Biopharma and Celsius Therapeutics, which are making novel drugs for treating IBD.
Last week, ABBV announced its intent to acquire privately held Nimble Therapeutics for $200 million in cash to explore the potential of novel oral therapies in immunology.
A newer entrant in this market space is Eli Lilly, whose IL-23p19 antibody Omvoh was approved by the FDA last year for use in UC indication. A regulatory filing for the drug is currently under review, seeking label expansion in CD indication.
Image: Bigstock
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
Sanofi (SNY - Free Report) and partner Teva Pharmaceuticals (TEVA - Free Report) announced positive data from the phase IIb RELIEVE UCCD study on their investigational anti-TL1A therapy, duvakitug (formerly TEV’574), for the treatment of Ulcerative Colitis (UC) and Crohn's disease (CD), the two main types of inflammatory bowel disease (IBD). The study met its primary endpoints for both diseases.
Treatment With SNY-TEVA Drug Exhibits Best-in-Class Potential
In the UC group, 36.2% of patients who received a low dose of the drug and 47.8% of patients who received a high dose achieved clinical remission compared to 20.45% for placebo.
For the CD group, 26.1% of patients who received a low dose and 47.8% of patients who took a high dose achieved endoscopic response compared to 13% in the placebo group.
Based on the above results and subject to regulatory discussions, Sanofi and Teva intend to start a late-stage study on the drug across both UC and CD indications.
The companies also plan to report detailed results from the RELIEVE UCCD study at a medical meeting next year.
Stock Performances of SNY & TEVA
Investors were impressed with the study results, which sent shares of both Sanofi and Teva soaring on Tuesday. Some Wall Street analysts even pointed out that the results for the Sanofi-Teva drug were even better than those reported by rivals Merck and Roche, which are also developing their respective anti-TL1A therapies.
Sanofi stock rose nearly 7%. Year to date, the stock fell 1.6% against the industry’s 5.3% growth.
Image Source: Zacks Investment Research
Shares of Teva jumped 26% post the announcement, even hitting a six-year high of $21.05. Year to date, the stock has doubled in market value compared with the industry’s 11.2% growth.
Image Source: Zacks Investment Research
Terms of Partnership Between SNY & TEVA
Last year, Sanofi in-licensed joint development and commercialization rights from Teva for duvakitug. Per the agreement terms, Teva will lead the commercialization of duvakitug in Europe, Israel and specified other countries, while Sanofi will be responsible for commercializing the drug in North America, Japan, other parts of Asia and the rest of the world.
Per the terms, Sanofi and Teva will equally share the development costs of duvakitug globally, as well as net profits and losses in major markets. In other markets, SNY will be liable to make tiered royalty payments to Teva on the drug’s net sales. Sanofi will lead the upcoming phase III development program for duvakitug.
In return for these rights, SNY paid TEVA an upfront payment of $500 million. Teva is also eligible to receive up to $1 billion in milestone payments.
Competition in the IBD Space
Both UC and CD indications are primary forms of IBD, marked by chronic inflammation in the gastrointestinal tract. In recent years, there has been a surge in the prevalence of these disorders due to genetic factors, environmental factors and lifestyle changes. Immune system irregularities, higher diagnosis rates, increased focus on early diagnosis and favorable reimbursement policies in developed countries drive the demand for IBD treatments.
The targeted IBD market is highly competitive. Some key players in this space are Johnson & Johnson (JNJ - Free Report) and AbbVie (ABBV - Free Report) , which have the strongest portfolios of immunology drugs and pipeline candidates.
J&J boasts a strong immunology portfolio with blockbusters like Stelara and Tremfya. A much older drug, Stelara, is already approved to treat several IBD indications, including CD and UC, across the United States and the European Union. J&J added more than $8 billion from Stelara sales in the first nine months of 2024.
Another successful drug in J&J’s portfolio is its newer immunology drug, Tremfya, which recorded sales of $2.7 billion in the first nine months of 2024. Tremfya was approved by the FDA for UC indication in September, with a similar regulatory filing under review in the European Union. It is also under review by the FDA and EMA for CD indication. J&J expects Tremfya to be a $5 billion product with potential approvals in both CD and UC indications.
ABBV’s key immunology products, Skyrizi and Rinvoq, are performing extremely well, bolstered by approval across multiple IBD indications, which should support top-line growth in the next few years. AbbVie has already raked in nearly $10 billion from the combined product sales of both these drugs in the first nine months of 2024.
ABBV has also been engaged in an acquisition spree since the beginning of this year to strengthen its leadership in the immunology space. In 2024, it acquired smaller biotechs, Landos Biopharma and Celsius Therapeutics, which are making novel drugs for treating IBD.
Last week, ABBV announced its intent to acquire privately held Nimble Therapeutics for $200 million in cash to explore the potential of novel oral therapies in immunology.
A newer entrant in this market space is Eli Lilly, whose IL-23p19 antibody Omvoh was approved by the FDA last year for use in UC indication. A regulatory filing for the drug is currently under review, seeking label expansion in CD indication.
Sanofi Price
Sanofi price | Sanofi Quote
Teva Pharmaceutical Industries Ltd. Price
Teva Pharmaceutical Industries Ltd. price | Teva Pharmaceutical Industries Ltd. Quote
Zacks Rank of SNY & TEVA
Sanofi and Teva currently carry a Zacks Rank #3 (Hold) each. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.